Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in the company's Ordinary Shares, filed pursuant to Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific insider trading disclosures and does not contain consolidated financial statements.
Material Changes
The filing details a specific transaction on February 10, 2014, involving Mr. S. Bicknell:
- Option Exercise: Exercised 12,650 options granted on December 2, 2004, at a price of £11.23 per share.
- Share Sale: Sold 12,650 Ordinary Shares at a price of £16.00 per share.
The company was advised of these transactions on February 11, 2014.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of director share transactions.
Investor Verification Checklist
- Verify the total number of shares held by Mr. S. Bicknell post-transaction.
- Confirm the exercise price (£11.23) and sale price (£16.00) against the market price on February 10, 2014.
- Review the 2001 GlaxoSmithKline Share Option Plan terms regarding the options exercised.